Clinical Trials registered on ClinicalTrials.gov - Accessed 13th July, 2018

Rank	Status	Study	
Rank	Status	, 	Yttrium-90 Transarterial Radioembolization in Patients With Advanced
		Hepatocellular Cancer	Tetrium 50 Transacteria Nadioembonization in Fatients With Advanced
1	Withdrawn	Condition:	Hepatocellular Cancer
		Interventions:	
			zation in NET After Lutetium-177-dotatate; an Efficacy Study
2	Recruiting		Neuroendocrine Tumors
	3		Device: Holmium-166 microspheres hepatic radioembolization.
			d Selective Internal Radioembolization Therapy for Unresectable Hepatic
		Metastases	
3	Active, not recruiting	Condition:	Neuroendocrine Tumors
	•	Interventions:	Drug: Pasireotide; Procedure: Sir-sphere Radioembolization; Drug: Everolimus
		Transarterial Radioemboliz	ation Versus Chemoembolization for the Treatment of Hepatocellular
		Carcinoma	
4	Unknown	Condition:	Hepatocellular Carcinoma
			Procedure: Transarterial Radioembolization: Procedure:
		Interventions:	Transarterial Chemoembolization using drug-eluting beads
		Study of Y90-Radioemboliz	ation With Nivolumab in Asians With Hepatocellular Carcinoma
5	Recruiting	Condition:	HepatoCellular Carcinoma
			Radiation: Y-90 Radioembolization; Drug: Nivolumab
			ation With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver
6	Dooreities	Metastases	
6	Recruiting		Colon Cancer; Rectal Cancer; Liver Metastases
			Drug: Tas-102; Device: SIR-Sphere
			In-Room Yttrium-90 Radioembolization Diagnostic Angiography and
7	Recruiting	Treatment	
·		Conditions:	Malignant Neoplasms of Digestive Organs; Metastatic Liver Tumors
		Intervention:	Device: SIR-Spheres
			fter Endovascular Radioembolization (LASER)
		Condition:	
8	Recruiting	Conditions	
	Treordining	Interventions:	Device: PET/MRI; Radiation: Percutaneous microwave ablation; Radiation: Stereotactic body radiotherapy
		Sorafenib and Radioembol	ization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
9	Completed	Condition:	Ocular Melanoma
3	Completed	Interventions:	Drug: Sorafenib; Device: Radioembolization with SIR-Spheres®
			(Yttrium Microspheres)
			Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary
		Liver Cancer, or Biliary Can	
			Adult Primary Hepatocellular Carcinoma;
			Advanced Adult Primary Liver Cancer;
10	Active, not recruiting	Conditions	Metastatic Extrahepatic Bile Duct Cancer;
10	Active, not recruiting	Conditions:	Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer;
			Stage D Adult Primary Liver Cancer (BCLC);
			Unspecified Adult Solid Tumor, Protocol Specific
			Procedure: PET scan; Procedure: CT Scan;
		Interventions:	Procedure: hepatic artery embolization
		Metastatic Colorectal Cano	er Liver Metastases Outcomes After Resin 90Y Microsphere
	_	Radioembolization in the L	•
11	Unknown †		Colorectal Cancer; Liver Metastases
		Intervention:	
			zation Versus ChemoEmbolization for the Treatment of Hepatocellular
		Carcinoma (HCC)	
12	Unknown	Condition:	Hepatocellular Carcinoma
		Interventions:	-
			s. Standard Microcatheter Use During Holmium-166 Radioembolization
13	Recruiting		Colorectal Neoplasms; Neoplasm Metastasis; Liver Diseases;
		Conditions:	Digestive System Neoplasms
		Intervention:	
	Terminated		Using Image Result for Positron Emission Tomography-Magnetic Resonance
14			ron Emission Tomography-Computed Tomography (PET/CT) in Patients With
		Liver Disease	
		Condition:	Liver Neoplasms
		Interventions:	
			ents With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are
			Radioembolization With Yttrium-90 Microspheres
15	Active, not recruiting		Neuroendocrine Tumors; Gastrointestinal Neoplasms;
		Conditions:	Carcinoid Tumors
		Interventions:	Drug: Lanreotide; Device: Y-90 microspheres
		-	- '

			b and SIR-Spheres® Microspheres Radioembolization in Patients With
16	Completed		rectal Cancer With Liver Metastases
	Completed		Colorectal Neoplasms
			Device: SIR-Spheres; Drug: Regorafenib
17			g to Detect Particle Distribution in Patients Undergoing Yttrium-90
	Unknown	Radioembolization Condition:	Carcinama Hanatacallular
		Intervention:	Carcinoma, Hepatocellular
		Prospective Post Y90 Liver	Hypertrophy
18	Active, not recruiting	Conditions:	
	, touve, met reer and g	Intervention:	7 71 1 7
			Shunting of Yttrium-90 Microspheres Using PET/CT
19	Active, not recruiting	Conditions:	Advanced Adult Primary Liver Cancer; Liver Metastases; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
		Interventions:	Procedure: positron emission tomography; Procedure: computed tomography
20	Recruiting	<u>Liver Metastasis</u>	ation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma
	557 \$111119	Condition:	
			Procedure: SIRT; Procedure: DSM-TACE
			rfusion and Post Y-90 TARE PET/CT Dosimetry
21	Recruiting		Hepatocellular Carcinoma
			Radiation: CT Liver Perfusion; Radiation: PET/CT of liver
			(Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular
22	Completed	Carcinoma and Treated Wi	
	•	Condition:	
		Intervention:	
22	Active not recruiting		py Guided by Primovist Enhanced MRI in Patients With Inoperable Liver
23	Active, not recruiting	Condition:	'
			Procedure: RFA; Procedure: Radioembolization (SIRT)
		CIRSE Registry for SIR-Sphe Condition:	
24	Recruiting	Interventions:	Liver Carcinoma Device: Yttrium-90 loaded SIR-Spheres microspheres; Behavioral: QLQ-C30 with HCC module
		90Y Transarterial Radioeml	bolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic
	Recruiting	<u>Cholangiocarcinoma</u>	
25		Condition:	Intrahepatic Cholangiocarcinoma
		Interventions:	Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
		Comparing HAI-90Y (SIR-sp Cancer	heres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal
26	Recruiting	Condition:	Colorectal Cancer
		Interventions:	Device: HAI-90Y radioembolization (SIR-spheres injection); Drug: systemic chemotherapy LV5FU2
			ted With Yttrium-90 for Hepatocellular Carcinoma
27	Recruiting	Condition:	Liver Neoplasms
		Intervention:	
			umab in Treating Patients With Microsatellite Stable Metastatic Colorectal
28	Not yet recruiting	Cancer to the Liver Conditions:	Metastatic Carcinoma in the Liver; MLH1 Gene Mutation; MSH6 Gene Mutation; PMS2 Gene Mutation; Stage IV Colorectal Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer
		Interventions:	Biological: Durvalumab; Other: Laboratory Biomarker Analysis; Biological: Tremelimumab
			ometastatic Solid Malignancies
	Recruiting	Condition:	0
29		Interventions:	Procedure: Complete Surgical Removal; Radiation: Stereotactic Radiosurgery; Radiation: Ablative external beam radiation dose; Procedure: Subtotal surgical removal plus ablative radiation dose; Radiation: Radioembolization
	Completed		atic Administration of Therasphere® in Association With Intravenous
0.0		Chemotherapy to Treat Ch	
30		Condition: Intervention:	Cholangiocarcinoma Radiation: Therasphere® in association with Gemcitabine and Cisplatin
	Active, not recruiting	Internal Radiation Therapy Versus Standard Dosimetry	for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry
31		Condition:	Adenoma, Liver Cell
•			Radiation: Optimized Internal Radiation Therapy;
		Interventions:	Radiation: Standard Internal Radiation Therapy

· .		1	
			rapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the
32	Recruiting	Treatment of Cholangiocel	
	J		Intrahepatic Cholangiocellular Carcinoma
			Procedure: DEB TACE; Procedure: SIRT
33	Unknown		E Trial to Study Blood Flow to Liver Metastases Metastatic Colorectal Cancer
			Other: Perfusion CT scan
		Prospective Tumor Respon	
34	Recruiting	Conditions:	
			Procedure: TACE; Procedure: Y-90; Procedure: MWA;
		Interventions:	Procedure: IRE
		Transarterial Radioemboliz	ation Versus Chemoembolization for the Treatment of Hepatocellular
35	Unknown	<u>Carcinoma</u>	
		Condition:	1
		Interventions:	Procedure: Transarterial Radioembolization; Procedure:
			Transarterial Chemoembolization using drug-eluting beads
			Yttrium-90 Transarterial Radioembolization in Patients With Advanced
36	Withdrawn	Hepatocellular Cancer	Harata allular Occasi
		Condition:	
		Interventions:	Drug: Sorafenib; Radiation: yttrium-90 radioembolization ration Versus ChemoEmbolization for the Treatment of Hepatocellular
		Carcinoma (HCC)	ration versus chemoembonzation for the freatment of nepatocential
37	Unknown	Condition:	Hepatocellular Carcinoma
		Interventions:	
			polization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic
		Cholangiocarcinoma	2
38	Recruiting	Condition:	Intrahepatic Cholangiocarcinoma
	3		Device: SIR-Spheres microspheres (Yttrium-90 Microspheres);
		Interventions:	Drug: Gemcitabine; Drug: Cisplatin
		Transarterial Radioembolis	ation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma
39	Pecruiting	<u>Liver Metastasis</u>	
39	Recruiting	Condition:	Uveal Melanoma
			Procedure: SIRT; Procedure: DSM-TACE
			rapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the
40	Recruiting	Treatment of Cholangiocel	
	3		Intrahepatic Cholangiocellular Carcinoma
			Procedure: DEB TACE; Procedure: SIRT
		Cholangiocarcinoma	bolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic
41	Recruiting	Condition:	Intrahepatic Cholangiocarcinoma
71	Recruiting		Device: SIR-Spheres microspheres (Yttrium-90 Microspheres);
		Interventions:	Drug: Gemcitabine; Drug: Cisplatin
		11C-Choline PET/CT and D\	NI MRI for Response Assessment of HCC Candidate to TARE
42	Recruiting	Condition:	Hepatocarcinoma
		Intervention:	Other: No intervention
		Transarterial Radioemboliz	ation Versus Chemoembolization for the Treatment of Hepatocellular
		<u>Carcinoma</u>	
43	Unknown	Condition:	Hepatocellular Carcinoma
		Interventions:	Procedure: Transarterial Radioembolization; Procedure:
			Transarterial Chemoembolization using drug-eluting beads
			Yttrium-90 Transarterial Radioembolization in Patients With Advanced
44	Withdrawn	<u>Hepatocellular Cancer</u> Condition:	Hanatacollular Cancar
		Interventions:	
			rfusion and Post Y-90 TARE PET/CT Dosimetry
45	Recruiting		Hepatocellular Carcinoma
	Neoralling		Radiation: CT Liver Perfusion; Radiation: PET/CT of liver
			apy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment
40	D 99		Intrahepatic Cholangiocellular Carcinoma
46	Recruiting		Procedure: DEB TACE; Procedure: SIRT
		Treatment for Bile Duct Cand	'
47	Recruiting		Cholangio Carcinoma
			Drug: SIRT Yttrium-90
	Active, not recruiting		nternal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced
48			Hepatocellular Carcinoma
			Device: SIR-Spheres; Drug: Sorafenib tosylate
			or Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus
49	Active, not recruiting	Condition:	Adenoma, Liver Cell
	, isare, not reordining	Interventions:	Radiation: Optimized Internal Radiation Therapy;
			Radiation: Standard Internal Radiation Therapy ns and Sir-Spheres for Liver Metastases
E0	Active not recruiting	CAN-1 Repatit Aftery Illiusio	· · · · · · · · · · · · · · · · · · ·
50	Active not recruiting	Condition	Liver Metastases
50	Active, not recruiting		Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres

5 4		SIRT Followed by CIS-GEM C	hemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of
	Descrition		Intrahepatic Cholangiocarcinoma
51	Recruiting	Interventions:	Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
		Prospective Post Y90 Liver H	
52	Active, not recruiting	Conditions:	Hepatocellular Carcinoma; Liver Hypertrophy
		Intervention:	Other: CT volumetric measurement after Y90 radioembolization
53	Recruiting	CIRSE Registry for SIR-Spher	<u>es Therapy</u>
		Condition:	Liver Carcinoma
		Interventions:	Device: Yttrium-90 loaded SIR-Spheres microspheres; Behavioral: QLQ-C30 with HCC module
54		Study of Y90-Radioemboliza	tion With Nivolumab in Asians With Hepatocellular Carcinoma
	Recruiting		HepatoCellular Carcinoma
			Radiation: Y-90 Radioembolization; Drug: Nivolumab
55	Active, not recruiting		Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary
			Colorectal Cancer Metastatic
			Drug: FOLFOX6m; Device: SIR-Spheres microspheres
			With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and
		Conditions:	Metastatic Cancer; Pancreatic Cancer
56	Unknown	Interventions:	Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres
		Study of Lanreotide in Patier	nts With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are
57	Active, not recruiting	Conditions:	Neuroendocrine Tumors; Gastrointestinal Neoplasms;
	-	Interventions	Carcinoid Tumors Drug: Laprestide: Device: Y-90 microspheres
			Drug: Lanreotide; Device: Y-90 microspheres res Treatment of Uveal Melanoma Metastasized to Liver
58	Active, not recruiting		Stage IV Uveal Melanoma
30	Active, not recruiting		Device: Sir-Spheres®
			nunting of Yttrium-90 Microspheres Using PET/CT
		Thot study to 765655 Early 51	Advanced Adult Primary Liver Cancer; Liver Metastases;
50	A stirry wast as a writing	Conditions:	Localized Unresectable Adult Primary Liver Cancer;
59	Active, not recruiting		Recurrent Adult Primary Liver Cancer
		Interventions:	Procedure: positron emission tomography;
		interventions.	Procedure: positron emission tomography; Procedure: computed tomography
		Efficacy Evaluation of Theras	Sphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
60	Terminated		Hepatocellular Carcinoma
			Device: TheraSphere; Drug: Sorafenib
0.4	A second second		eres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or
61	Active, not recruiting		Liver Cancer; Metastatic Cancer
			Drug: capecitabine; Radiation: yttrium Y 90 glass microspheres d With Yttrium-90 for Hepatocellular Carcinoma
62	Recruiting		Liver Neoplasms
02	Recruiting	Intervention:	Liver Neoplasins
			Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced_
63	Active, not recruiting		Hepatocellular Carcinoma
	, , , , , , , , , , , , , , , , , , ,		Device: SIR-Spheres; Drug: Sorafenib tosylate
			tion in Comparison to Transarterial Chemoembolisation in Uveal Melanoma
64	Recruiting		Uveal Melanoma
	Ŭ		Procedure: SIRT; Procedure: DSM-TACE
			ass Microspheres for Advanced Hepatocellular Carcinoma (HCC)
65	Active, not recruiting	Condition:	Liver Cancer
65			Drug: Sorafenib; Radiation: Yttrium-90 Microspheres;
	Active, not recruiting	Interventions:	
	Active, not recruiting		Behavioral: Follow-Up Phone Calls
		CAR-T Hepatic Artery Infusio	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases
66	Active, not recruiting	CAR-T Hepatic Artery Infusion:	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases Liver Metastases
		CAR-T Hepatic Artery Infusion: Condition: Interventions:	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres
66	Active, not recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary
		CAR-T Hepatic Artery Infusion: Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions:	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Metastases Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-
66	Active, not recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions:	Behavioral: Follow-Up Phone Calls ns and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Metastases Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres
66	Active, not recruiting Completed	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions:	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer
66	Active, not recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition:	Behavioral: Follow-Up Phone Calls Ins and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Metastases Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma
66	Active, not recruiting Completed	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention:	Behavioral: Follow-Up Phone Calls Ins and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere
66 67 68	Active, not recruiting Completed Active, not recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal
66	Active, not recruiting Completed	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Condition:	Behavioral: Follow-Up Phone Calls Ins and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Metastases Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal Colorectal Cancer Metastatic
66 67 68	Active, not recruiting Completed Active, not recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Intervention:	Behavioral: Follow-Up Phone Calls ons and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Metastases Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal Colorectal Cancer Metastatic Device: TheraSphere
66 67 68 69	Active, not recruiting Completed Active, not recruiting Recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Intervention: Radiolabeled Glass Beads (T	Behavioral: Follow-Up Phone Calls Ins and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Metastases Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal Colorectal Cancer Metastatic Device: TheraSphere Device: TheraSphere Device: TheraSphere Device: TheraSphere
66 67 68	Active, not recruiting Completed Active, not recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Intervention: Radiolabeled Glass Beads (Tour Condition:	Behavioral: Follow-Up Phone Calls Instance Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal Colorectal Cancer Metastatic Device: TheraSphere Device: TheraSphere Device: TheraSphere Device: TheraSphere Device: TheraSphere
66 67 68 69	Active, not recruiting Completed Active, not recruiting Recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Intervention: Radiolabeled Glass Beads (T Condition: Intervention:	Behavioral: Follow-Up Phone Calls Instance and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal Colorectal Cancer Metastatic Device: TheraSphere
66 67 68 69	Active, not recruiting Completed Active, not recruiting Recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Intervention: Radiolabeled Glass Beads (T Condition: Intervention: Radiolabeled Glass Beads (T Condition: Intervention: 90Y Transarterial Radioembo	Behavioral: Follow-Up Phone Calls Ins and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal Colorectal Cancer Metastatic Device: TheraSphere Device: TheraSphere
66 67 68 69	Active, not recruiting Completed Active, not recruiting Recruiting	CAR-T Hepatic Artery Infusion Condition: Interventions: FOLFOX Plus SIR-SPHERES M Conditions: Interventions: Efficacy Evaluation of Theras Condition: Intervention: Efficacy Evaluation of Theras Condition: Intervention: Radiolabeled Glass Beads (T Condition: Intervention: Radiolabeled Glass Beads (T Condition: Intervention: 90Y Transarterial Radioembo	Behavioral: Follow-Up Phone Calls Instance and Sir-Spheres for Liver Metastases Liver Metastases Biological: anti-CEA CAR-T cells; Device: Sir-Spheres ICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer; Colorectal Carcinoma; Liver Metastases Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres Sphere in Patients With Inoperable Liver Cancer Unresectable Hepatocellular Carcinoma Device: TheraSphere Sphere Following Failed First Line Chemotherapy in Metastatic Colorectal Colorectal Cancer Metastatic Device: TheraSphere

		Internal Padiation Thoras : 1	or Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus
			Adenoma, Liver Cell
72	Active, not recruiting		Radiation: Optimized Internal Radiation Therapy;
		Interventions:	Radiation: Standard Internal Radiation Therapy
73			tion Versus ChemoEmbolization for the Treatment of Hepatocellular
	Unknown		Hepatocellular Carcinoma
			Drug: TACE-DEB; Drug: 90Y-RE volumab for Uveal Melanoma With Liver Metastases
74			Uveal Melanoma; Hepatic Metastases
	Recruiting		Device: SIR-Spheres® Yttrium 90; Drug: ipilimumab;
		Interventions:	Drug: nivolumab
75		Tas-102 and Radioembolizat	ion With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver
	Recruiting		Colon Cancer; Rectal Cancer; Liver Metastases
			Drug: Tas-102; Device: SIR-Sphere
76	Recruiting		eres Data Collection in Unresectable Liver Cancer: the RESIN Study
			Localized Non-Resectable Adult Liver Carcinoma Other: Yttrium-90 Resin Microspheres
			Glass Microspheres in Treating Patients With Advanced Liver Cancer
		TVIVOIGITIAD AND TELLIAM 1 50	Stage IIIA Hepatocellular Carcinoma;
			Stage IIIB Hepatocellular Carcinoma;
77	Pooruiting	Conditions:	Stage IIIC Hepatocellular Carcinoma;
''	Recruiting		Stage IVA Hepatocellular Carcinoma;
			Stage IVB Hepatocellular Carcinoma
		Interventions:	Other: Laboratory Biomarker Analysis; Biological: Nivolumab;
			Radiation: Yttrium Y 90 Glass Microspheres r Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization
78	Unknown		Colorectal Cancer; Liver Metastases
	S.II.G.	Intervention:	5.5.55ta. Galissi, Live Motastasso
			eres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal
79	Recruiting	Condition:	Colorectal Cancer
'5	recruiting	Interventions:	Device: HAI-90Y radioembolization (SIR-spheres injection);
			Drug. Systemic chemotherapy LVSFO2
			and SIR-Spheres® Microspheres Radioembolization in Patients With
80	Completed		Colorectal Neoplasms
			Device: SIR-Spheres; Drug: Regorafenib
81	Withdrawn		<u>'ttrium-90 Transarterial Radioembolization in Patients With Advanced</u> Hepatocellular Cancer
01	vvitnarawn		Drug: Sorafenib; Radiation: yttrium-90 radioembolization
			ic Administration of Therasphere® in Association With Intravenous
00	Completed		Cholangiocarcinoma
82			Radiation: Therasphere® in association with Gemcitabine and Cisplatin
		intervention:	Madialion. Therasonerew in association with Gemcitabine and Cispiatin 1
——			
		Radiolabeled Glass Beads in	Treating Patients With Liver Cancer That Cannot be Removed by Surgery
		Radiolabeled Glass Beads in	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma;
82	Recruiting	Radiolabeled Glass Beads in Conditions:	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer;
83	Recruiting		Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer;
83	Recruiting	Conditions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
83	Recruiting		Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer;
83	Recruiting	Conditions:	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres;
		Conditions: Interventions: SIRT Followed by CIS-GEM C	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis nemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma
83	Recruiting Not yet recruiting	Conditions: Interventions: SIRT Followed by CIS-GEM C Condition:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy
		Interventions: SIRT Followed by CIS-GEM C Condition: Interventions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis nemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
84	Not yet recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance
		Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition:	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms
84	Not yet recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions:	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT
84	Not yet recruiting Terminated	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis Demotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT cer in the Liver
84	Not yet recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition:	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis nemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT cer in the Liver Cholangio Carcinoma
84	Not yet recruiting Terminated	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention:	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis Demotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT cer in the Liver
84	Not yet recruiting Terminated	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intervention: Intervention:	Treating Patients With Liver Cancer That Cannot be Removed by Surgery Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90
84 85 86	Not yet recruiting Terminated Recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intervention: Intervention: Condition: Intervention: Intra-arterial Y-90 TheraSph Condition:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT cer in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 eres for Hepatic Metastases From Solid Tumors
84 85 86	Not yet recruiting Terminated Recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT cer in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 eres for Hepatic Metastases From Solid Tumors Liver Neoplasms
84 85 86	Not yet recruiting Terminated Recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) Ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT Cer in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Deres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres
84 85 86	Not yet recruiting Terminated Recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Deres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer
84 85 86 87	Not yet recruiting Terminated Recruiting Completed	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Internal Radiation Therapy N Conditions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Peres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and
84 85 86 87	Not yet recruiting Terminated Recruiting Completed	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Internal Radiation Therapy N Conditions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Peres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy;
84 85 86 87	Not yet recruiting Terminated Recruiting Completed	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Interventions: Interventions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Press for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 resin microspheres
84 85 86 87 88	Not yet recruiting Terminated Recruiting Completed Unknown	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intra-arterial Y-90 TheraSph Condition: Intervention: Intervention: Intervention: Intervention: Interventions: Interventions: Interventions: Interventions: Interventions: Interventions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis nemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Peres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 resin microspheres ed for Treating Patients With Primary Liver Cancer When Surgery is Not an
84 85 86 87	Not yet recruiting Terminated Recruiting Completed	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Interventions: Interventions: Interventions: Interventions: Interventions: Conditions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Peres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 resin microspheres ed for Treating Patients With Primary Liver Cancer When Surgery is Not an Liver Cancer; Hepatoma
84 85 86 87 88	Not yet recruiting Terminated Recruiting Completed Unknown	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention: Interventions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis nemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Peres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 resin microspheres ed for Treating Patients With Primary Liver Cancer When Surgery is Not an
84 85 86 87 88	Not yet recruiting Terminated Recruiting Completed Unknown	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intra-arterial Y-90 TheraSph Condition: Intervention: Intervention: Intervention: Interventions: Interventions: Interventions: Interventions: Interventions: Interventions: Interventions: Interventions: Intervention: Intervention: Intervention: Intervention: Intervention: Intervention:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 eres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres ed for Treating Patients With Primary Liver Cancer When Surgery is Not an Liver Cancer; Hepatoma Device: Yttrium 90 (TheraSphere)
84 85 86 87 88	Not yet recruiting Terminated Recruiting Completed Unknown Enrolling by invitation	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intervention: Intervention: Intervention: Interventions: Interventions: Interventions: Interventions: Interventions: Interventions: Interventions: Intervention: Humanitarian Device Exemp Conditions: Interventions:	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis nemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Peres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres ed for Treating Patients With Primary Liver Cancer When Surgery is Not an Liver Cancer; Hepatoma Device: Yttrium 90 (TheraSphere) tion (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular Carcinoma, Hepatocellular; Liver Cancer
84 85 86 87 88 89	Not yet recruiting Terminated Recruiting Completed Unknown Enrolling by invitation Recruiting	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intra-arterial Y-90 TheraSph Condition: Intervention: Intervention: Intervention: Interventions: Interventions: Interventions: Interventions: Intervention: Radiolabeled Glass Beads Us Conditions: Intervention: Humanitarian Device Exemp Conditions: Intervention: Radiolabeled Glass Beads in	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis memotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) Ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT Iver in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Inverse for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres defor Treating Patients With Primary Liver Cancer When Surgery is Not an Liver Cancer; Hepatoma Device: Yttrium 90 (TheraSphere) tion (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular Carcinoma, Hepatocellular; Liver Cancer Device: TheraSphere Treatment Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
84 85 86 87 88	Not yet recruiting Terminated Recruiting Completed Unknown Enrolling by invitation	Interventions: SIRT Followed by CIS-GEM C Condition: Interventions: Microsphere Localization Us Condition: Interventions: Treatment for Bile Duct Can Condition: Intervention: Intervention: Intra-arterial Y-90 TheraSph Condition: Intervention: Intervention: Intervention: Interventions: Interventions: Interventions: Interventions: Intervention: Radiolabeled Glass Beads Us Conditions: Intervention: Humanitarian Device Exemp Conditions: Intervention: Radiolabeled Glass Beads in	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis nemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Intrahepatic Cholangiocarcinoma Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) ing Image Result for Positron Emission Tomography-Magnetic Resonance Liver Neoplasms Device: PET/MR; Device: PET/CT ter in the Liver Cholangio Carcinoma Drug: SIRT Yttrium-90 Peres for Hepatic Metastases From Solid Tumors Liver Neoplasms Device: TheraSphere, Yttrium-90 glass Microspheres Vith Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Metastatic Cancer; Pancreatic Cancer Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres ed for Treating Patients With Primary Liver Cancer When Surgery is Not an Liver Cancer; Hepatoma Device: Yttrium 90 (TheraSphere) tion (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular Carcinoma, Hepatocellular; Liver Cancer

		Intervention:	Radiation: yttrium Y 90 glass microspheres
92	Unknown	Chemotherapy and Internal	Radiation in Treating Patients With Colorectal Cancer That Has Spread to the
		Conditions:	Colorectal Cancer; Metastatic Cancer
		Interventions:	Drug: floxuridine; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
93	Unknown	Transarterial Radioemboliza	tion Versus Chemoembolization for the Treatment of Hepatocellular
		Condition:	Hepatocellular Carcinoma
		Interventions:	Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads